Jim Vasselli

Dr. Jim Vasselli is chief medical officer of Aulos and brings extensive knowledge and proficiency gained through more than 25 years leading oncology research and development projects across a broad array of tumor types and therapeutic modalities. Most recently, Dr. Vasselli served as senior vice president of clinical development at Maverick Therapeutics (now Takeda), where he progressed a conditionally active CD3 x EGFR bispecific molecule from preclinical studies to a first-in-human clinical trial. Prior to Maverick, Dr. Vasselli served as vice president of clinical research at MacroGenics, developing clinical strategy and overseeing execution of Phase I and 2 studies for multiple immuno-oncology assets, including CD3-engaging bispecifics, monoclonal antibodies and antibody drug conjugate compounds. He also spent nine years at AstraZeneca/MedImmune leading early clinical development of the anti-PD-L1 drug durvalumab and pivotal trials of the kinase inhibitor vandetanib. Dr. Vasselli began his career in academic research with 10 years at the National Institutes of Health, National Cancer Institute, in a surgical oncology fellowship evaluating IL-2 in patients with kidney cancer and melanoma and as a Basic Science Research Fellow in the NCI Urology Branch.

Dr. Vasselli received a B.A. in Engineering from Lafayette College and an M.D. from New York Medical College. He completed a general surgical residency at Morristown Memorial Hospital.